Ventyx Biosciences, Inc. (VTYX) Financials
Newest figures come from the 10-Q for Q3 FY2025, filed Nov 6, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VTYX SEC filings page.
This page shows Ventyx Biosciences, Inc. (VTYX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Ventyx Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Ventyx Biosciences, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Ventyx Biosciences, Inc. reported a net loss of $135.1M while operations used $130.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Ventyx Biosciences, Inc.'s EBITDA was -$24.8M in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 35.6% from the same quarter a year earlier. Against the prior quarter it is up 15.3%.
Ventyx Biosciences, Inc. reported -$22.8M in net income in Q3 2025. This represents an increase of 35.2% from the same quarter a year earlier. Against the prior quarter it is up 15.4%.
Ventyx Biosciences, Inc. earned -$0.32 per diluted share (EPS) in Q3 2025. This represents an increase of 36.0% from the same quarter a year earlier. Against the prior quarter it is up 15.8%.
Not reported for Q3 2025.
Cash & Balance Sheet
Ventyx Biosciences, Inc. recorded an outflow of $17.6M in free cash flow in Q3 2025, representing a cash shortfall after capex. This represents an increase of 50.5% from the same quarter a year earlier. Against the prior quarter it is up 17.6%.
Ventyx Biosciences, Inc. held $32.0M in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Margins & Returns
Ventyx Biosciences, Inc.'s ROE was -11.9% in Q3 2025, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.
Not reported for Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
Capital Allocation
Ventyx Biosciences, Inc. invested $17.7M in research and development in Q3 2025. This represents a decrease of 42.2% from the same quarter a year earlier. Against the prior quarter it is down 20.5%.
Ventyx Biosciences, Inc. invested $50K in capex in Q3 2025, funding long-term assets and infrastructure. Against the prior quarter it is up 19.0%.
Not reported for Q3 2025.
VTYX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $17.7M-42.2% | $22.3M-19.9% | $22.9M-32.1% | N/A | $30.6M-38.4% | $27.8M-42.7% | $33.7M-4.8% | N/A |
| SG&A Expenses | $7.2M-9.5% | $7.1M-10.6% | $7.2M-10.2% | N/A | $7.9M-3.4% | $7.9M-7.9% | $8.0M+12.7% | N/A |
| Operating Income | -$24.9M+35.5% | -$29.3M+17.9% | -$30.1M+27.9% | N/A | -$38.6M+33.5% | -$35.7M+37.5% | -$41.8M+1.8% | N/A |
| EBITDA | -$24.8M+35.6% | -$29.2M+17.9% | -$30.0M+28.1% | N/A | -$38.5M+33.6% | -$35.6M+37.6% | -$41.7M+1.9% | N/A |
| Net Income | -$22.8M+35.2% | -$27.0M+15.5% | -$27.4M+28.9% | N/A | -$35.2M+34.8% | -$31.9M+40.0% | -$38.6M+0.9% | N/A |
| EPS (Basic) | -$0.32+36.0% | -$0.38+24.0% | -$0.39+37.1% | -$0.41+48.1% | -$0.50+45.7% | -$0.50+45.1% | -$0.62+8.8% | -$0.79-23.4% |
| EPS (Diluted) | -$0.32+36.0% | -$0.38+24.0% | -$0.39+37.1% | -$0.41+48.1% | -$0.50+45.7% | -$0.50+45.1% | -$0.62+8.8% | -$0.79-23.4% |
| Diluted Shares (Avg) | 71M+0.9% | 71M+0.9% | 71M+15.0% | N/A | 71M+20.0% | 71M+20.5% | 62M+7.3% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
VTYX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $211.5M-29.8% | $230.0M-25.6% | $253.5M-23.7% | $276.6M-0.4% | $301.1M-6.4% | $309.2M-11.3% | $332.1M-14.7% | $277.7M-25.2% |
| Current Assets | $201.1M-30.5% | $219.3M-14.6% | $242.6M-24.1% | $229.6M-13.1% | $289.4M-6.1% | $256.9M-25.9% | $319.8M-17.4% | $264.3M-20.1% |
| Cash & Equivalents | $32.0M-48.2% | $32.3M-21.1% | $28.1M-80.2% | $27.3M-47.1% | $61.8M+9.1% | $40.9M-20.9% | $141.9M+122.9% | $51.6M-20.4% |
| Short-Term Investments | $160.7M-24.6% | $176.7M-11.0% | $200.7M+24.9% | $190.1M-5.3% | $213.1M-12.8% | $198.5M-29.2% | $160.7M-48.7% | $200.6M-20.7% |
| Long-Term Investments | $0 | $0-100.0% | $0 | $35.6M | $0 | $40.3M | $0 | $0-100.0% |
| Total Liabilities | $20.1M-10.0% | $20.6M-27.4% | $21.8M-12.9% | $22.5M-33.3% | $22.3M-41.3% | $28.4M+35.5% | $25.1M+42.9% | $33.8M+92.9% |
| Current Liabilities | $11.3M-8.5% | $11.5M-36.6% | $12.4M-14.7% | $12.8M-42.6% | $12.3M-53.1% | $18.1M-9.6% | $14.5M-12.0% | $22.3M+36.1% |
| Non-Current Liabilities | $8.8M-11.8% | $9.2M-11.0% | $9.5M-10.4% | $9.7M-15.3% | $10.0M-15.4% | $10.3M+1016.5% | $10.5M+918.1% | $11.5M+903.9% |
| Total Equity | $191.4M-31.4% | $209.4M-25.4% | $231.6M-24.5% | $254.0M+4.1% | $278.8M-1.7% | $280.8M-14.3% | $307.0M-17.4% | $243.9M-31.1% |
| Retained Earnings | -$631.6M-20.3% | -$608.7M-24.3% | -$581.7M-27.1% | -$554.3M-32.2% | -$525.0M-41.0% | -$489.7M-53.8% | -$457.8M-72.6% | -$419.2M-85.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
VTYX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.5M+50.6% | -$21.3M+13.3% | -$25.7M+46.0% | -$23.2M+55.0% | -$35.5M-2.3% | -$24.5M+50.2% | -$47.6M-54.0% | -$51.7M-9.3% |
| Depreciation & Amortization | $100K0.0% | $100K0.0% | $100K+42.9% | $65K+8.3% | $100K+203.0% | $100K+194.1% | $70K+125.8% | $60K+30.4% |
| Stock-Based Compensation | $4.6M-15.6% | $4.6M-20.7% | $5.0M-23.1% | N/A | $5.5M-31.9% | $5.8M-26.7% | $6.5M-0.4% | N/A |
| Capital Expenditures | $50K | $42K-30.0% | $16K-90.9% | $6K-97.2% | $0-100.0% | $60K-69.2% | $175K+191.7% | $211K+88.4% |
| Free Cash Flow | -$17.6M+50.5% | -$21.3M+13.3% | -$25.7M+46.2% | -$23.3M+55.2% | -$35.5M-2.2% | -$24.6M+50.3% | -$47.8M-54.3% | -$51.9M-9.5% |
| Investing Cash Flow | $17.1M-41.7% | $25.2M+133.4% | $26.4M-36.8% | -$11.0M-123.8% | $29.2M-24.8% | -$75.5M-316.9% | $41.8M+321.0% | $46.1M+132.7% |
| Financing Cash Flow | $203K-99.2% | N/A | N/A | -$25K-104.3% | $26.9M+1553.0% | -$906K-136.6% | $96.2M+97.7% | $585K+105.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VTYX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -11.9%+0.7pp | -12.9%-1.5pp | -11.8%+0.7pp | N/A | -12.6%+6.4pp | -11.4%+4.9pp | -12.6%-2.1pp | N/A |
| Return on Assets | -10.8%+0.9pp | -11.7%-1.4pp | -10.8%+0.8pp | N/A | -11.7%+5.1pp | -10.3%+4.9pp | -11.6%-1.6pp | N/A |
| Current Ratio | 17.86-5.7x | 19.12+4.9x | 19.57-2.4x | 17.97+6.1x | 23.52+11.8x | 14.19-3.1x | 22.00-1.4x | 11.87-8.3x |
| Debt-to-Equity | 0.100.0x | 0.100.0x | 0.090.0x | 0.090.0x | 0.08-0.1x | 0.100.0x | 0.080.0x | 0.14+0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ventyx Biosciences, Inc. VTYX | FY2024 | N/A | -$135.1M | N/A | $1.0B | — |
| Caribou Biosciences, Inc. CRBU | FY2025 | $11.2M | -$148.1M | N/A | $130.8M | 52/100 |
| Aardvark Therapeutics, Inc. AARD | FY2025 | $5.1M | -$57.6M | N/A | $109.2M | 55/100 |
| Nuvectis Pharma, Inc. NVCT | FY2025 | N/A | -$26.4M | N/A | $715.6M | — |
| Milestone Pharmaceuticals Inc. MIST | FY2025 | N/A | -$63K | N/A | $100.8M | — |
| SANGAMO THERAPEUTICS INC SGMO | FY2025 | $39.6M | -$122.9M | N/A | $55.9M | — |
Where Ventyx Biosciences, Inc. Ranks
Frequently Asked Questions
Is Ventyx Biosciences, Inc. profitable?
No, Ventyx Biosciences, Inc. (VTYX) reported a net income of -$135.1M in fiscal year 2024.
What is Ventyx Biosciences, Inc.'s EBITDA?
Ventyx Biosciences, Inc. (VTYX) had EBITDA of -$148.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ventyx Biosciences, Inc.'s return on equity (ROE)?
Ventyx Biosciences, Inc. (VTYX) has a return on equity of -53.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Ventyx Biosciences, Inc.'s free cash flow?
Ventyx Biosciences, Inc. (VTYX) recorded an outflow of $131.1M in free cash flow during fiscal year 2024. This represents a 21.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ventyx Biosciences, Inc.'s operating cash flow?
Ventyx Biosciences, Inc. (VTYX) recorded an outflow of $130.9M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Ventyx Biosciences, Inc.'s total assets?
Ventyx Biosciences, Inc. (VTYX) had $276.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Ventyx Biosciences, Inc.'s capital expenditures?
Ventyx Biosciences, Inc. (VTYX) invested $241K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Ventyx Biosciences, Inc. spend on research and development?
Ventyx Biosciences, Inc. (VTYX) invested $117.0M in research and development during fiscal year 2024.
What is Ventyx Biosciences, Inc.'s current ratio?
Ventyx Biosciences, Inc. (VTYX) had a current ratio of 17.97 as of fiscal year 2024, which is generally considered healthy.
What is Ventyx Biosciences, Inc.'s debt-to-equity ratio?
Ventyx Biosciences, Inc. (VTYX) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ventyx Biosciences, Inc.'s return on assets (ROA)?
Ventyx Biosciences, Inc. (VTYX) had a return on assets of -48.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does Ventyx Biosciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, Ventyx Biosciences, Inc. (VTYX) held $252.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $130.9M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Ventyx Biosciences, Inc.'s Piotroski F-Score?
Ventyx Biosciences, Inc. (VTYX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ventyx Biosciences, Inc.'s earnings high quality?
Ventyx Biosciences, Inc. (VTYX) reported a net loss of $135.1M while operations used $130.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.